ChiCTR2000029734 版本V1.3 版本创建时间2020/02/12 02:47:59 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000029734 

最近更新日期:

Date of Last Refreshed on:

2020-02-12 02:47:23 

注册时间:

Date of Registration:

2020-02-10 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

金远香医生:请与我们联系上传伦理批件 新型冠状病毒肺炎(COVID-19)流行病学调查与临床特征分析

Public title:

Epidemiological investigation and clinical characteristics analysis of novel coronavirus pneumonia (COVID-19)

注册题目简写:

English Acronym:

研究课题的正式科学名称:

新型冠状病毒肺炎(COVID-19)流行病学调查与临床特征分析

Scientific title:

Epidemiological investigation and clinical characteristics analysis of novel coronavirus pneumonia (COVID-19)

研究课题代号(代码):

Study subject ID:

湖南省自然科学基金(2017JJ3250和2019JJ40230)、湖南省卫健委科研基金(B2019034 和 B2019035)

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

金远香 

研究负责人:

仇成凤 

Applicant:

Chengfeng Qiu 

Study leader:

Chengfeng Qiu 

申请注册联系人电话:

Applicant telephone:

+86 18774567407

研究负责人电话:

Study leader's
telephone:

+86 14786531725

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

jinwei36@126.com

研究负责人电子邮件:

Study leader's E-mail:

qiuchengfeng0721@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

怀化市鹤城区锦溪南路144号

研究负责人通讯地址:

怀化市鹤城区锦溪南路144号

Applicant address:

144 Jinxi Road South, Hecheng District, Huaihua, Hu'nan, China

Study leader's address:

144 Jinxi Road South, Hecheng District, Huaihua, Hu'nan, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

怀化市第一人民医院

Applicant's institution:

The First People's Hospital of Huaihua

研究负责人所在单位:

怀化市第一人民医院

Affiliation of the Leader:

The First People's Hospital of Huaihua

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY-2020013102

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

怀化市第一人民医院伦理委员会

Name of the ethic committee:

Ethics Committee of Huaihua First People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

仇成凤

Contact Name of the ethic committee:

Qiu Chengfeng

伦理委员会联系地址:

怀化市鹤城区锦溪南路144号

Contact Address of the ethic committee:

144 Jinxi Road South, Hecheng District, Huaihua, Hu'nan, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

怀化市第一人民医院

Primary sponsor:

The First People's Hospital of Huaihua

研究实施负责(组长)单位地址:

怀化市鹤城区锦溪南路144号

Primary sponsor's address:

144 Jinxi Road South, Hecheng District, Huaihua, Hu'nan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖南

市(区县):

怀化

Country:

China

Province:

Hu'nan

City:

Huaihua

单位(医院):

怀化市第一人民医院

具体地址:

怀化市鹤城区锦溪南路144号

Institution
hospital:

The First People's Hospital of Huaihua

Address:

144 Jinxi Road South, Hecheng District

经费或物资来源:

湖南省自然科学基金(2017JJ3250和2019JJ40230)、湖南省卫健委科研基金(B2019034 和 B2019035)

Source(s) of funding:

Hunan Provincial Natural Science Foundation (2017JJ3250 and 2019JJ40230), Hunan Provincial Health and Medical Committee Research Fund (B2019034 and B2019035)

研究疾病:

新型冠状病毒(COVID-19)肺炎  

Target disease:

Novel Coronavirus Pneumonia (COVID-19)

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

探明新冠状病毒感染患者的流行病学分布和比较患者的临床特证。  

Objectives of Study:

Finding out the epidemiological distribution of patients with novel coronavirus infection and comparing their clinical characteristics.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

经RC-PCR检测新冠脉病毒阳性和二代测序确诊的新冠脉病毒感染的患者。

Inclusion criteria

Patients who are positive for novel coronary virus detected by RC-PCR and second-generation sequencing.

排除标准:

Exclusion criteria:

No

研究实施时间:

Study execute time:

From 2020-01-31 00:00:00 To 2020-08-07 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-02-08 00:00:00 To 2020-08-07 00:00:00

干预措施:

Interventions:

组别:

观察组

样本量:

40

Group:

Case series

Sample size:

干预措施:

干预措施代码:

Intervention:

N/A

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖南 

市(区县):

怀化 

Country:

China

Province:

Hu'nan

City:

Huaihua

单位(医院):

怀化市第一人民医院 

单位级别:

三甲医院 

Institution
hospital:

The First People's Hospital of Huaihua

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

流行病学史

指标类型:

主要指标

Outcome:

Epidemiological history

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规指标

指标类型:

主要指标

Outcome:

haematological

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

首发症状

指标类型:

主要指标

Outcome:

First symptom

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生物指标

指标类型:

主要指标

Outcome:

blood glucose

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血糖

指标类型:

主要指标

Outcome:

blood glucose

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

预后

指标类型:

主要指标

Outcome:

prognosis

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血气分析

指标类型:

主要指标

Outcome:

Blood gas analysis

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生命体征

指标类型:

附加指标

Outcome:

vital signs

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

基础疾病史

指标类型:

次要指标

Outcome:

Basic disease history

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

并发症

指标类型:

主要指标

Outcome:

complication

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究采取连续入组方式收集研究对象,不适合随机方法

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

N/A

Blinding:

N/A

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

随文章发表

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Published with article

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2020-02-11 11:33:51